Share Twitter LinkedIn Facebook Email Dr. Ross Camidge, University of Colorado, discusses management of CNS progression for ALK-positive NSCLC including monitoring frequency and preferences between systemic and radiation therapy. Advertisement
ASCO 2025: Lung Cancer Immunotherapy Breakthroughs from the Immuno-Oncology Symposium Lung Cancer Treatment 4 Mins Read